Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
Status:
Completed
Trial end date:
2019-05-16
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of filanesib when given together
with carfilzomib in treating patients with multiple myeloma or plasma cell leukemia that has
returned or does not respond to treatment. Drugs used in chemotherapy, such as filanesib,
work in different ways to stop the growth of cancer cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. Carfilzomib may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving
filanesib together with carfilzomib may be a better treatment for multiple myeloma or plasma
cell leukemia.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Array BioPharma National Cancer Institute (NCI) Onyx Therapeutics, Inc.